Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...
Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...
Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland (ots) - Leading Big Data company developing platform with clinical and genomic data from 5 million subjects, to transform drug development and bring clinical benefits to patients. BC Platforms, a world leader in genomic data management solutions, today ...
Lausanne (ots) - Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group(TM) (www.debiopharm.com), announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically ...
Québec, Canada/Lausanne, Switzerland (ots) - GenePOC announces the commercialization of its Clostridium difficile and Group B Strep molecular tests in Europe, along with onboarding additional partners to cover the EMEA market GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is proud to announce that it has started the commercialization of its first two CE-IVD marked tests, GenePOC(TM) CDiff and GenePOC(TM) GBS ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced three communications ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary gland cancer ...
Lausanne, Switzerland and Atlanta (ots/PRNewswire) - Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1143 for treatment of Ovarian Cancer affecting around 154 ...
Mandaluyong, Philippines and Lausanne, Switzerland (ots/PRNewswire) - Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for the distribution ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, is proud to congratulate its partner Yakult's commitment in obtaining approval for a supplemental new drug application for Elplat® in postoperative ...
Lausanne, Switzerland (ots/PRNewswire) - Recommended Dose reached and early signs of efficacy seen Debiopharm International SA (Debiopharm) - part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company - today announced significant milestones in the clinical development of the SMAC mimetic ...
Lausanne, Switzerland (ots/PRNewswire) - - Applicable to a wide variety of sample types to isolate bacteria, viruses, tumor cells, etc. - FibroTrap improves sensitivity and shortens time taken from sample collection to results - Spinomix to focus on the development of its flagship MagPhase technology Debiopharm ...
Lausanne, Switzerland (ots/PRNewswire) - One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet ...
Lausanne, Switzerland (ots/PRNewswire) - For non-US media - Global Rosacea Tweetathon set to bring the realities of living with rosacea under the spotlight #ChatRosacea Today the world's first Global Rosacea Coalition, supported by the National Rosacea Society and many leading rosacea experts, called for greater ...
Lausanne, Switzerland (ots) - Ecole hôtelière de Lausanne (EHL) deploys its strategic development objectives under the leadership of its Board of Governors. The newly formed "EHL SA" holding company aims to ensure the management of its various specialized business units. This holding company structure rationalizes ...
Lausanne, Switzerland (ots/PRNewswire) - GenePOC is a Canadian company which has developed a rapid, innovative, low cost MDx platform for the detection of infectious diseases Debiopharm Diagnostics [https://www.debiopharm.com/about-us/debiopharm-diagnostics-s-a.html ], part of Debiopharm Group [https://www.debiopharm.com/about-us/debiopharm-group.html ](TM), is proud ...
Lausanne, Switzerland (ots/PRNewswire) - - Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement with Novartis to regain full rights to Alisporivir (DEB025) currently completing two Phase 2 studies of interferon-free treatment in ...
Lausanne, Switzerland (ots/PRNewswire) - - Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received Fast Track designation for ABSSSI (acute bacterial skin and skin structure infections) - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) ...
Lausanne (ots) - Ecole hôtelière de Lausanne (EHL), the Conrad N. Hilton College at the University of Houston and the School of Hotel and Tourism Management (SHTM) at The Hong Kong Polytechnic University (PolyU) join forces to offer an exceptional new Master's program in Global Hospitality Business. Representatives from the three leading universities in hospitality management and industry partners join a conference ...
Lausanne (ots) - IMD, a top-ranked global business school, just released its first annual World Talent Report. The report introduces the IMD World Talent Ranking based on the long-established IMD World Competitiveness Yearbook. It assesses a country's ability to develop, attract and retain talent for companies based on three factors: 1] Investment and ...
Lausanne, Switzerland (ots/PRNewswire) - - Galderma, in partnership with the International League of Dermatological Societies, has launched the search for initiatives that will fulfil an important role in strengthening the global dermatology community - The SKINPACT Awards, part of a wider programme with social ...